Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Malaysia ETF (EWM) vs Gilead Sciences, Inc. (GILD) Price & Performance

iShares MSCI Malaysia ETFTrade
Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

iShares MSCI Malaysia ETF vs Gilead Sciences, Inc. — how do they compare? iShares MSCI Malaysia ETF trades at $28.07, while Gilead Sciences, Inc. trades at $135.67 (market cap $164.99B). The key difference: Gilead Sciences, Inc. pays a 2.47% dividend while iShares MSCI Malaysia ETF pays none. Which is the better fit depends on your goals.

EWMGILD
Sector
Broad Market / FactorHealth
52-Week High
$30.42$155.80
52-Week Low
$24.73$110.56
Market Cap
$164.99B
Enterprise Value
$188.06B
Dividend Yield
2.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Malaysia ETF

EWM (iShares MSCI Malaysia ETF) trades at $28.18, up 0.28% with a bullish technical signal from moving averages. The ETF offers concentrated exposure to Malaysia's financial (54%) and industrial (21%) sectors, benefiting from data center expansion and tourism initiatives. Key support and resistance cluster around $28, with neutral oscillators suggesting balanced momentum.

Outlook remains positive due to Malaysia's structural growth drivers, though financial ratios are unavailable. Risks include energy supply constraints and regional currency volatility. Institutional sentiment leans bullish with 11 buy signals, but investors should monitor Malaysia's economic policies and global macro conditions.

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Malaysia ETF

EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.

Read more on EWM

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD